OCT 03, 2016 09:23 AM PDT

Metastatic Tumors Outsmart the Immune System

WRITTEN BY: Kara Marker
Why can the immune system recognize and attack primary tumors but not metastatic tumors? Researchers from the University of British Columbia, in collaboration with the Vancouver Prostate Centre, have the answer.
Biopsy of a highly differentiated squamous cell carcinoma of the mouth.
According to results from a study of human cancer patients, some individuals with prostate or renal cancer tumors showed an exceptional loss of an immune protein called interleukin-33 (IL-33). Without IL-33, cancer cells were able to “hide” from the immune system, and these patients were more likely to see their cancer return within five years.

After further investigating the role of IL-33 in immune evasion by cancer cells, researchers saw that effector T lymphocytes responsible for targeting tumors, like cytotoxic T cells, rely on IL-33 as a signal for denoting if a cell is cancerous. "IL-33 could be among the first immune biomarkers for prostate cancer and we are planning to examine this in a larger sample size of patients," said first author Iryna Saranchova.

The loss of IL-33 occurs in epithelial carcinomas, the cancers that initially develop in the lining of organs: prostate, kidney, breast, lung uterine, cervical, pancreatic, skin, and many more. Compared to other interleukins in the same family, IL-33 has unique intracellular and extracellular features. Inside the cell, IL-33 helps maintain barrier function by regulating gene expression, and outside the cell IL-33 is in charge of immune defense and repair mechanisms while simultaneously triggering the differentiation of helper T cells during the adaptive immune response.

IL-33 also works through a protein complex called major histocompatibility complex (MHC) to alert circulating effector T lymphocytes to the presence of a cancer cell. In addition to signaling the presence of cancer, MHC binds peptide fragments derived from pathogens for display on the cell surface so T cells will be aware of a microbial invasion. Even if MHC is present and functioning, without IL-33, the signaling process is ineffective. 

For cancer patients with epithelial carcinomas, monitoring levels of IL-33 could be an effective way to track the progression of their cancer. Additionally, resupplying cancerous cells with IL-33 could help the immune system start to recognize and attack again, according to results from the study. More experiments will be conducted to confirm the efficacy and safety of this treatment in clinical trials.

The present study was recently published in the journal Scientific Reports.
 


Sources: The University of British Columbia, Nature Immunology, Immunobiology: The Immune System in Health and Disease 5th edition, Journal of Cellular Physiology
About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
JUL 28, 2018
Immunology
JUL 28, 2018
IgM Antibody Protects against HIV-1 Infection
The antibody IgM is shown to be provide protection against HIV infection in rhesus monkeys up to 82 days past exposure to HIV....
AUG 22, 2018
Immunology
AUG 22, 2018
Immune Response Runs on the Body Clock
Immune cell functions such as inflammation are dictated by your bodies circadian rhythm, responding daily to external stimuli on a 24 hour schedule....
SEP 11, 2018
Immunology
SEP 11, 2018
Oops! I Broke My DNA
Innate Immune System, DNA Damage and Repair...
OCT 14, 2018
Immunology
OCT 14, 2018
Malaria Vesicles Activating Immune Responses
Red blood cells infected with malaria will secrete small vesicles that activate pathogen receptors...
OCT 31, 2018
Drug Discovery
OCT 31, 2018
New Drug Target For a Rare Lymphoma
The promise of immunotherapy in oncology is stronger than ever. Now, an international team of scientists and physicians from the Research Institute of the ...
NOV 07, 2018
Immunology
NOV 07, 2018
Inflammation Can Steal Your Sleep
A link between inflammation and the circadian rhythm has been determined in mouse models. High-fat-diets may be the cause....
Loading Comments...